brivanib and its Impurities
"Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC). It is under investigation for the treatment of HepatoCellular Carcinoma. . Reference standards of Brivanib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below
1-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy)propan-2,3,3,3-d4-2-ol
1-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy)propan-2,3,3,3-d4-2-ol
Catalogue No.:PA STI 088922
CAS :
NA
Molecular Formula : C19H15D4FN4O3
Molecular Weight : 374.41